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Background: The main concern in formulation of antibodies is the intrinsic instability of these labile compounds.
To evaluate the physicochemical stability of antibody in dry powder formulations, physical stability of IgG1 and a
monoclonal antibody (trastuzumab) during the spray drying process was studied in a parallel study and the efficacy
of some sugar based excipients in protection of antibodies was studied.
Results: The SDS-PAGE analysis showed no fragmentation of antibodies after spray drying in all formulations. The
secondary structure of antibodies contained 40.13 to 70.19% of β structure in dry state. Also, CD spectroscopy showed
the similar secondary structure for trastuzumab after reconstitution in water. ELISA analysis and cell culture studies were
conducted in order to evaluate bioactivity of monoclonal antibody. Formulations containing combination of excipients
provided maximum tendency of trastuzumab to attach to the ELISA antigen (86.46% ± 2.3) and maximum bioactivity
when incubated with SKBr3 cell line (the cell viability was decreased to 65.99% ± 4.6). Incubation of formulations with
L929 cell line proved the biocompatibility of the excipients and non-toxic composition of formulations.
Conclusion: The IgG1 and trastuzumab demonstrated similar behavior in spray drying process. The combination of
excipients containing trahalose, hydroxypropyl beta cyclodextrin and beta cyclodextrin with proper ratio improved the
physical and chemical stability of both IgG1 and monoclonal antibody.
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Monoclonal antibodies as an important part of thera-
peutic proteins are approved for treatment of various
chronic and life threatening diseases. Their specific ac-
tion and relatively low side effects have contributed to
vast application of antibodies in many diseases [1]. The
majority of antibodies are administrated by injection or-
dinarily; however, new antibodies and new administra-
tion routes such as inhalation [2], transdermal [3],
vaginal [4], oral [5] and nasal [6] are investigated broadly
as new delivery systems.
The main concern in formulation of antibodies is the
intrinsic instability of these labile compounds. Generally,* Correspondence: vatanara@tums.ac.ir
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unless otherwise stated.proteins are sensitive molecules to various physical in-
stabilities like denaturation, aggregation, fragmentation
and chemical reactions such as deamination, oxidation
and isomerization [7,8]. Embedding of protein in dry
matrix improves the stability versus physical and chem-
ical degradation by various mechanisms [9-11].
Spray drying as a one-step process has been widely
studied in production of dry powders containing pro-
teins [12]. As a limitation, proteins as like as antibodies
could be destabilized due to the high temperature and
pressures in this process. In this way, the effects of vari-
ous excipients [9,12] and process variables [12,13] have
been investigated in lots of studies [9,10,12,13]. In our
previous study, D-optimal design was conducted to
optimize IgG1 formulation in the presence of sugars and
cyclodextrins in order to understand how the spray dry-
ing affects the antibody. But as like as many otherral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cessing of IgG as a model antibody and extension of the
results of a general antibody to the monoclonal anti-
bodies remains as a challenge. To the extent of our
knowledge, no systematic study has been reported as a
comparison between these two categories of antibodies.
In the present work, trastuzumab as a monoclonal anti-
body was formulated parallel to the IgG1 in the presence
of sugar based excipients and the physical stability were
compared. Trastuzumab is an important humanized
monoclonal antibody that is approved in treatment of
breast cancer with over-expressed HER2 receptor
[14,15]. So, assessment of the biological activity of tras-
tuzumab is supportive to evaluate the conformational
stability of protein during the process.
Material and methods
Materials
Hydroxypropyl beta cyclodextrin (HPβCD) was obtained
from Acros (Belgium) and Beta cyclodextrin (βCD) was
purchased from Sigma (USA). Trehalose dehydrate, potas-
sium phosphate dibasic and disodium sulfate were acquired
from Merck (Germany). Trastuzumab (Herceptin®) was
purchased from Roche Ltd (Hungary) and the chemicals
were from sigma (USA). Human IgG1 (with molecular
weight of about 150 KD) was supplied by Kedrion (Italy).
Prior to each investigation, low molecular weight additive
of antibody solution was removed by dialysis with deionized
water (cut off: 15 kDa).
Spray drying of antibody formulations
Spray drying was performed on various aqueous solu-
tions of antibody with different excipients according to
Table 1. The design of study was in accordance with the
findings of previous studies on IgG1. A lab scale Buchi-
191 spray dryer (Buchi, Switzerland) was employed to
obtain the dry antibody powder. The inlet temperature
of 100°C, air flow rate of 700 L/h, liquid feed rate ofTable 1 Composition of various formulations of IgG1 and
trastuzumab
Formulation IgG1 Trastuzumab HPβCD βCD Trehalose
F1 - 1 - - -
F2 - 1 1 - -
F3 - 1 - 1 -
F4 - 1 - - 1
F5 - 1 1 1 0.26
F6 1 - - - -
F7 1 - 1 - -
F8 1 - 1 -
F9 1 - - 1
F10 1 - 1 1 0.261.7 mL/min, and aspiration rate of 100% were selected.
The resulted dry powders were collected in dry and well
closed glass vials and stored at 4°C.
Size exclusion chromatography
Size exclusion chromatography (SEC) was conducted to
evaluate the percentage of soluble IgG aggregations as
one of the most important physical instabilities. In order
to separate the monomer from aggregated antibody, a
300 mm TSK 3000 SWXL column (Tosoh Biosep,
Germany) was employed. Approximately, 20 μL of each
sample containing 2.5 mg/mL was injected. The mobile
phase consisted of 0.1 M disodium hydrogen phosphate
and 0.1 M sodium sulfate (pH 6.8) with flow rate of
0.5 mL/min. The antibody concentration was measured
by a UV detector (Waters, USA) at 280 nm. All experi-
ments were performed in triplicate.
Sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE)
In order to determine the antibody fragmentation, non-
reducing sodium dodecyl sulphate-poly (acrylamide) gel
electrophoresis (SDS-PAGE) was performed. Polyacryl-
amide gel 10% was prepared and diluted sample with con-
centration of 100 μg/mL was loaded. The samples were
mixed with equal volumes of sample buffer before loading.
Protein molecular weight marker of Fermentas® (Germany)
was used to estimate the sample molecular weight.
Fourier transformation infrared spectroscopy (FT-IR)
Nicolet Magna spectrometer (USA) was applied to record
the infrared spectra. Briefly, 2 mg of each sample was
pressed with 200 mg KBr to make a clear tablet. The Jasco
Spectra Manager® software (Japan) was used to deconvo-
lution the spectra and detect the changes in secondary
structure of antibody. Second derivative spectrum of
amide I region (1600–1700 cm−1) is a useful indicator toFigure 1 The percent of antibody monomer in microparticles
immediately after spray drying analyzed by size exclusion
chromatography (SEC).
Figure 2 Size exclusion chromatography of F5 (A); as shown, the aggregation related pick (B) has been disappeared in this formulation.
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α helix and turn was calculated by mixed Gaussian/
Lorentzian function considering β sheet structure absorp-
tion in 1640 cm−1 and 1695–1690 cm−1, α helix in 1660–
1650 cm−1 and turns from 1690 to1665 cm−1.Circular dichroism (CD)
Circular dichroism spectroscopy (AVIV, USA) was ap-
plied to analysis the secondary structure of monoclonal
antibody after reconstitution. Proper amounts of proc-
essed powder were dissolved in purified water to make
250 μg/mL solutions. Measurement of buffer and anti-
body samples were performed in far-UV spectrophotom-
eter at 20°C from 195 to 260 nm with the interval of
1 nm. Buffer spectra were substracted from the relevant
protein solutions and converted to mean residual ellipti-
city. Deconvolution was performed to estimate the sec-
ondary structure of trastuzumab spectra. The secondary
structure was calculated considering the molecular
weight of 148 kDa for trastuzumab and a total number
of 1328 amino acids.Figure 3 SDS-PAGE of formulations contained trastuzumab and IgG1.Enzyme-linked Immunosorbent Assay (ELISA)
Direct ELISA was performed in order to determine the
in-vitro activity of spray dried trastuzumab. Briefly, a 96
wells plate from Nunc (USA) was coated with 6 μg/mL
of recombinant human HER2 protein in carbonate/bicar-
bonate buffer over-night. The plate was blocked with
2% w/v BSA for 1 h at 37°C after three times of washing.
About 100 μL of samples were added and incubated for
2 h at 37°C. After washing, 100 μL of the goat anti hu-
man antibody conjugated with horse radish peroxidase
(HRP) was added and incubated at room temperature
for 1 h. The bounded antibody was determined with tet-
ramethyl benzemidine (TMB) as the proxidase substrate
for 15 min and the concentration was determined at
650 nm by a STAT FAX 4700 ELISA reader (USA).Cell culture studies
The human breast cancer cell line SKBr3 and human
fibroblast L929 were obtained from cell culture collection
of Pasteur institute of Iran. SKBr3 was cultured in RPMI
medium supplemented with 10% of fetal bovine albuminsThe standard molecular weights were run in the left of gel.
Figure 4 Amount of β structure in dry state analyzed by FTIR in
various samples.
Figure 5 Amount of β structure of spray dried trastuzumab
after reconstitution in water analyzed by CD.
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Eagle’s medium with 5% of fetal bovine albumin. Both cul-
ture mediums contained 1% of L-glutamine, 100 UI/mL of
penicillin G and 100 mg/mL of streptomycin and main-
tained at 37°C in a humid atmosphere of 5% CO2. For the
experiment, the cells were harvested after brief incubation
with trypsin (0.05%, w/v) and EDTA (0.02%, w/v).
Primarily, the cells were incubated with various concen-
trations of trastuzumab in the range of 101 to 106 ng/mL
and the dose–response of trastuzumab on SKBr3 cells was
determined. Further examinations were performed on the
samples in concentrations of 105 ng/mL. To evaluate the
biological activity of monoclonal antibody in various spray
dried samples, the proper amount of each sample were
dissolved in 100 mL of medium and added to 96-well
plates in triplicate with 2 × 102 cells/well. Cell viability was
assayed with mono tetrazolium 3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyl tetrazolium bromide (MTT) colorimetric
method. Briefly, the cells were exposed to tetrazolium
after 48 h incubation with trastuzumab samples. Living
cells were able to metabolized tetrazolium to non-soluble
formazan, the formazan salts was dissolved and quantified
using spectrophotometer plate reader (BioTek, USA) at
540 nm. The negative control was medium without trastu-
zumab and the positive control included unprocessed
standard trastuzumab with determined concentration.
Statistical analysis
Data are presented as means ± SD and LSD-test was per-
formed to evaluate the differences between groups. The
statistical significancy of results is considered with a P
value less than 0.05. The graphs have been drawn by
GraphPad® Prism 5and Microsoft® Excel 2007.
Results and discussion
Similar to other proteins, antibodies can undergo deg-
radation pathways during the spray drying process. Pro-
tein degradation can reduce the efficient binding of
protein to the receptors and decrease the bioactivity. So
it is very impotent to ensure the physical stability as well
as biological activity of monoclonal antibodies after
spray drying or other processes. In our previous study,
optimization and characterization of IgG1formulations
led to use a combination of trehalose, HPβCD and βCD
which resulted in protection of antibody structure up to
99.81 ± 0.7%. In the present study, as shown in Table 1,
these excipients were employed in order to evaluate the
stability of trastuzumab as a monoclonal antibody in
comparison with IgG1.
Physical stability of antibody
The percent of antibody aggregates after spray drying
are presented in Figure 1. The pattern of aggregation in
IgG1 and trastuzumab was similar; however, the percentof aggregations were different. As seen, the pure IgG1
contained 87.1% monomer and pure trastuzumab con-
tained 98.9% monomer after process. Application of ex-
cipients successfully decreased the aggregation in both
of antibodies. In this way, the efficacy of HPβCD was
greater than βCD and trehalose. Combination of trehal-
ose, HPβCD and βCD in the F5 showed the highest ef-
fectiveness in protection of the trastuzumab monomer.
As seen in Figure 2, the pick related to the trastuzumab
dimmer in SEC chromatogram has been disappeared.
This point implicates the synergistic effect of sugars in
protection of antibody monomer. Similar observations
have demonstrated the synergism effect of various sugars
in preservation of proteins by water substitution mech-
anism [10].
Non reducing SDS-PAGE was performed in order to re-
veal fragmentation of antibodies during the spray drying.
In this type of SDS-PAGE, reducing agents are not used
and consequently, evaluation of protein structure is pos-
sible without reduction of di-sulfide bounds. Therefore,
Figure 6 The Affinity of trastuzumab to Her2 antigen in various
spray dried formulations by ELISA study.
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tion would be possible. As shown in Figure 3, all formula-
tions of both trastuzumab and IgG1 present bonds just in
150 kDa and there is no distinct bond in lower molecular
weight regions. Amphlett G et al. (1996) showed that the
bonds such as Asp-Gly and Asp-Pro are more sensitive to
cleavage in proteins backbone. So the proteins are prone
to cleavage and fragmentation in these places [16]. More-
over, disulfide bonds cleavage lead to formation of anti-
body fragments of 25 and 50 kDa. If fragmentation took
place during the spray drying process, we expected to ob-
serve the distinct bonds in SDS-PAGE gel, but the results
suggested that process stresses did not affect the trastuzu-
mab backbone. So the data implicated that the short time
exposure of antibodies to harsh conditions of spray drying
did not induce antibody fragmentation.
The secondary structure of antibody samples was eval-
uated by FTIR spectroscopy in dry state. As presented in
Figure 4, the lowest ratio of β structures (40.13 ± 2.1%)
was perceived when pure antibodies were processed by
spray drying and presence of excipients in the formula-
tions of antibody increased the β structures content;
Where, F2 provided 69.35% and F5 contained 70.19% ofFigure 7 The survived SKBr3 and L929 cell line after incubation with 1β structure. Processing of pure IgG1 lead similarly to
41.01% of β structures and F10 as the formulation con-
taining the composition of excipients, preserved the high
amounts of β structure after spray drying (67.21%).
The secondary structure of monoclonal antibody, after
reconstitution in water, was assessed using far-UV CD
spectrophotometer. The amounts of β sheet and β turns
in the processed trastuzumab were about 60%. Compari-
son of FTIR and CD data revealed that dehydration of
trastuzumab resulted in substantial and measurable con-
formational changes and it emphasize that protein struc-
ture is highly depended on protein type and formulation
conditions, but these changes can be reversible or irre-
versible. According to the Figure 5, results indicated that
trastuzumab reforms to the native structure after recon-
stitution in water. In agreement, similar studies showed
that selection of proper stabilizers minimize the struc-
tural changes of proteins such as poly-L-lysine [17], acet-
ate dehydrogenase and phosphor fructokinase [18].
Biological activity
The biological activity of trastuzumab depends on its abil-
ity to target the extracellular domain of human epidermal
growth factor receptor protein in tumor cells. Trastuzu-
mab therapy reduces the tumor cells proliferation by sev-
eral mechanisms. On the one hand, it promotes cell cycle
arrest and apoptosis in tumor or metastatic cells and on
the other hand, it activates an antibody-dependent cellular
cytotoxicity (ADCC) response with the aid of natural killer
(NK) cells. The NK cells induce cell death by attaching to
the Fc domain of antibody and the activity of trastuzumab
highly depends on the ability to contact with HER2 anti-
gen as well as NK cells receptors.
ELISA is an appropriate method for simultaneous
evaluation of both Fc and Fab fragments of antibody;
since, in this analysis method, the structural changes in
the antibody are exaggerated. Any change in the Fab or
Fc can affect the affinity of antibody to the antigen or
secondary antibody. Direct ELISA was applied to evalu-
ate the stability of trastuzumab during the spray drying05 ng/mL of trastuzumab in various formulations.
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controls. As presented in Figure 6, just 43.2 ± 0.2% of
the pure antibody was quantified after processing;
whereas, presence of excipients in F2 and F5 enhanced
the affinity of antibody to the antigen up to 79.9 ± 0.1%
and 86.5 ± 2.3%, respectively.
Furthermore, bioactivity of monoclonal antibody was
evaluated by means of HER2-over-expressing breast can-
cer cell line (SKBr3). The cells were incubated in the
presence of 105 ng/mL of spray dried samples and un-
processed standard trastuzumab as positive control. The
cells viability was evaluated by MTT assay after 48 hours.
Statistical comparison of survived cells after incubation
showed that the ability of F1 containing processed pure
trastuzumab to kill the cells was the minimum (Figure 7).
The 2-side dunnett test indicated no difference between
F1 and negative control. However, the unprocessed tras-
tuzumab presented a great activity to kill the SKBr3 cells
(with the minimum cell viability of 65.88 ± 3.95% after
incubation). The ANOVA with the aid of post doc (LSD)
test among spray dried formulations indicated the equal
ability of F2, F3, F4 with F5, which showed the greatest
ability to preserve the antibody activity (65.99 ± 4.6%).
Also, LSD test indicated no difference between F5 and
positive control. As a result, it could be deduced that
combination of various excipients with different proper-
ties led to inhibition of aggregation and preservation of
antibody structure as well as protection of amino acids
in the protein backbone.
Some previous studies indicated the citotoxicity of
cyclodextrine and other derivatives on the body cells or
on red blood cells [19,20]. The L929 is a fibroblast cell
line L929 without any HER2 antigen on the surface that
is suitable for evaluation of toxicity and biocompatibility
of formulations. The same concentration of trastuzumab
was incubated with this cell line and analysis of cell via-
bility in the presence of different formulations showed
no toxic effect at concentrations of 105 ng/mL and the
100% of cells were alive after incubation with various
formulations after 48 hr (Figure 7). Consequently, we
concluded that the death in SKBr3 cells were due to the
active trastuzumab rather than formulation excipients.
Also the biocompatibility of formulations was confirmed
in this experiment.
Conclusion
This report focused on physicochemical stability and
biological activity of antibodies after spray-drying. Com-
bination of HPβCD, βCD and trehalose provided the
maximum efficacy in protection of the IgG1 as a general
antibody and trastuzumab as a monoclonal antibody.
Coexistence of these excipients in the formulations pre-
served monomers up to 99.1% and 99.9% for IgG and
trastuzumab, respectively.The conformational changes of processed antibodies
in dry structure were reversible and it could reform to
the native stricter after reconstitution in water. The ac-
tivity of trastuzumab in best formulation was detected
up to 86.46% in ELISA test and it was confirmed by cell
culture studies.
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